Early highly active antiretroviral therapy enhances B-cell longevity: A 5 year follow up

Pediatric Infectious Disease Journal

Volumn 33, Issue 5, 2014, Pages

  Cagigi, Alberto ^a   Rinaldi, Stefano ^b   Cotugno, Nicola ^a   Manno, Emma Concetta ^a   Santilli, Veronica ^a   Mora, Nadia ^a   Zangari, Paola ^a   Aquilani, Angela ^a   Tchidjou, Kuekou Hyppolite ^a   Giaquinto, Carlo ^c   Bernardi, Stefania ^a   Rossi, Paolo ^a   Palma, Paolo ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

protective humoral immunity; routine childhood immunization; vaccination design

Indexed keywords

CD27 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; IMMUNOGLOBULIN D; MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PNEUMOCOCCUS VACCINE; TETANUS ANTIBODY; ANTIBODY; ANTIRETROVIRUS AGENT; VACCINE;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIPHTHERIA; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HAEMOPHILUS INFECTION; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNE SENESCENCE; IMMUNOMODULATION; LYMPHOCYTE COUNT; MALE; MEASLES; MEMORY CELL; MUMPS; PERTUSSIS; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PRIORITY JOURNAL; REVACCINATION; RUBELLA; SENESCENCE; TETANUS; VACCINATION; BLOOD; CELL SURVIVAL; HIV INFECTIONS; IMMUNOLOGY; PHYSIOLOGY; PROCEDURES; TIME; YOUNG ADULT;

ADOLESCENT; ANTI-RETROVIRAL AGENTS; ANTIBODIES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; B-LYMPHOCYTES; CELL SURVIVAL; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; TIME FACTORS; VACCINES; YOUNG ADULT;

EID: 84899471528     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000144     Document Type: Article

References (21)

1. Pensieroso S, Cagigi A, Palma P, et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proc Natl Acad Sci USA. 2009;106:7939-7944.
2. Palma P, Romiti ML, Cancrini C, et al. Delayed early antiretroviral treatment is associated with an HIV-specific long-term cellular response in HIV-1 vertically infected infants. Vaccine. 2008;26:5196-5201.
3. Moir S, Malaspina A, Ho J, et al. Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J Infect Dis. 2008;197:572-579.
4. Colonna-Romano G, Bulati M, Aquino A, et al. A double-negative (IgD-CD27-) B cell population is increased in the peripheral blood of elderly people. Mech Ageing Dev. 2009;130:681-690.
5. Buffa S, Bulati M, Pellicanò M, et al. B cell immunosenescence: different features of naive and memory B cells in elderly. Biogerontology. 2011;12:473-483.
6. Bulati M, Buffa S, Candore G, et al. B cells and immunosenescence: a focus on IgG+IgD-CD27-(DN) B cells in aged humans. Ageing Res Rev. 2011;10:274-284.
7. Cagigi A, Cotugno N, Giaquinto C, et al. Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions. Hum Vaccin Immunother. 2012;8:1784-1794.
8. Titanji K, De Milito A, Cagigi A, et al. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood. 2006;108:1580-1587.
9. Menson EN, Mellado MJ, Bamford A, et al. Guidance on vaccination of HIV-infected children in Europe. HIV Med. 2012;13:333-336.
10. Cagigi A, Rinaldi S, Santilli V, et al. Premature ageing of the immune system relates to increased anti-lymphocyte antibodies (ALA) after an immunization in HIV-1-infected and kidney-transplanted patients. Clin Exp Immunol. 2013;174:274-280.
11. Sutcliffe CG, Moss WJ. Do children infected with HIV receiving HAART need to be revaccinated? Lancet Infect Dis. 2010;10:630-642.
12. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007;357:1903-1915.
13. Spoulou VI, Tsoumas DL, Papaevangelou VG, et al. Immunogenicity and immunological memory induced by a 7-valent pneumococcal CRM197 conjugate vaccine in symptomatic HIV-1 infected children. Vaccine. 2005;23:5289-5293.
14. Capolunghi F, Cascioli S, Giorda E, et al. CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. J Immunol. 2008;180:800-808.
15. Jaspan HB, Lawn SD, Safrit JT, et al. The maturing immune system: implications for development and testing HIV-1 vaccines for children and adolescents. AIDS. 2006;20:483-494.
16. Siegrist CA. Neonatal and early life vaccinology. Vaccine. 2001;19:3331-3346.
17. Cagigi A, Du L, Dang LV, et al. CD27(-) B-cells produce class switched and somatically hyper-mutated antibodies during chronic HIV-1 infection. PLoS One. 2009;4:e5427.
18. Frasca D, Diaz A, Romero M, et al. Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans. Vaccine. 2010;28:8077-8084.
19. Frasca D, Landin AM, Lechner SC, et al. Aging down-regulates the transcription factor E2A, activation-induced cytidine deaminase, and Ig class switch in human B cells. J Immunol. 2008;180:5283-5290.
20. Khurana S, Frasca D, Blomberg B, et al. AID activity in B cells strongly correlates with polyclonal antibody affinity maturation in-vivo following pandemic 2009-H1N1 vaccination in humans. PLoS Pathog. 2012;8:e1002920.
21. Cagigi A, Pensieroso S, Ruffin N, et al. Relation of activation-induced deaminase (AID) expression with antibody response to A(H1N1)pdm09 vaccination in HIV-1 infected patients. Vaccine. 2013;31:2231-2237.